Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Operations (2016 - 2025)

Lexaria Bioscience's Cash from Operations history spans 11 years, with the latest figure at 984098.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 63.9% year-over-year to 984098.0; the TTM value through Nov 2025 reached 8708440.0, down 33.91%, while the annual FY2025 figure was 10450387.0, 110.74% down from the prior year.
  • Cash from Operations for Q4 2025 was 984098.0 at Lexaria Bioscience, up from 2642498.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 619614.0 in Q1 2024 and bottomed at 3583953.0 in Q2 2025.
  • The 5-year median for Cash from Operations is 1252221.5 (2022), against an average of 1516710.45.
  • The largest YoY upside for Cash from Operations was 63.9% in 2025 against a maximum downside of 183.08% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 1166324.0 in 2021, then dropped by 6.77% to 1245313.0 in 2022, then rose by 5.11% to 1181653.0 in 2023, then tumbled by 130.7% to 2726045.0 in 2024, then surged by 63.9% to 984098.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Cash from Operations are 984098.0 (Q4 2025), 2642498.0 (Q3 2025), and 3583953.0 (Q2 2025).